🇺🇸 FDA
Patent

US 10928391

CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease

granted A61KA61K39/3955A61K47/6807

Quick answer

US patent 10928391 (CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K39/3955, A61K47/6807